Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis

Yang-Hua Fan; Miao-Jing Wu; Yuan Jiang; Minhua Ye; Shi-Gang Lu; Lei Wu; Xin-Gen Zhu

doi:10.18632/oncotarget.15247

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis

Yang-Hua Fan, Miao-Jing Wu, Yuan Jiang, Minhua Ye, Shi-Gang Lu, Lei Wu and Xin-Gen Zhu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:21410-21417. https://doi.org/10.18632/oncotarget.15247

Metrics: PDF 1551 views | HTML 1821 views | ?

Abstract

Yang-Hua Fan1,*, Miao-Jing Wu1,*, Yuan Jiang1, Minhua Ye1, Shi-Gang Lu1, Lei Wu1, Xin-Gen Zhu1

1Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, People’s Republic of China

*These authors have contributed equally to the work

Correspondence to:

Xin-Gen Zhu, email: [email protected]

Lei Wu, email: [email protected]

Keywords: HULC, neoplasm, metastasis, prognosis, meta-analysis

Received: September 09, 2016 Accepted: January 17, 2017 Published: February 10, 2017

ABSTRACT

Since the long non-coding RNA HULC (Highly Upregulated in Liver Cancer) is dysregulated in many cancers, we performed a meta-analysis to determine its prognostic potential in malignant tumors. We searched electronic databases, including PubMed, Medline, OVID, Cochrane Library and Web of Science from inception until August 14, 2016 and identified seven studies with 730 cancer patients for the meta-analysis. We analyzed the hazard ratios (HRs) and 95% confidence intervals (CIs) to determine the relationship between HULC expression and overall survival (OS). We also using RevMan5.3 software to calculate odds ratio (ORs) to assess the association between HULC expression and pathological parameters, including lymph node metastasis (LNM), distant metastasis (DM) and the tumor stage. Our analysis showed that higher HULC expression was associated with OS (HR= 0.50, 95% CI: 0.35–0.70, P <0.00001), LNM (OR=0.20, 95 % CI 0.06–0.64), DM (OR=0.27, 95% CI: 0.13–0.54) and the tumor stage (OR=0.39, 95 % CI 0.25–0.64). These meta-analysis data demonstrate that higher HULC expression can be a useful prognostic biomarker in human cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15247

Publication Alerts

Research Papers:

Long non-coding RNA HULC as a potential prognostic biomarker in human cancers: a meta-analysis

Abstract